Carbylan Therapeutics's (CBYL) Phase 3 Trial of Hydros-TA in Patients With OA of Knee Meets One Primary Endpoint, Misses Second Primary Endpoint

February 1, 2016 4:29 PM

(Updated - February 1, 2016 5:24 PM EST)Carbylan Therapeutics (NASDAQ: CBYL), a specialty pharmaceutical company focused on the development of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found